TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30599693

Group type: EXPERIMENTAL
Intervention: Physics-based statistics modeling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 26306418

Group type: EXPERIMENTAL
Intervention: Behavioural therapy intervention provided by trained pharmacists (stimulus control and sleep restriction) over three pharmacy visits (baseline, 1 and 3 months follow-up)
Number of subjects: 46
Study: 24878363

Group type: EXPERIMENTAL
Intervention: Moist heat (MHG)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Dry heat (DHG)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 198
Study: 21952697

Group type: COMPARATOR
Intervention: Normal-birth-weight (NBW) infants, n=183
Number of subjects: 66
Study: 19833998

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent housing, vocational training, and work
Number of subjects: 206

Group type: COMPARATOR
Intervention: Abstinence-contingent housing, vocational training, work, plus cognitive behavioral day treatment
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Consecutive weeks of abstinence during treatment
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Older age and male gender
Number of subjects: 206
Study: 17390417

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 66
Study: 15658951

Group type: EXPERIMENTAL
Intervention: BIBN4096BS 2.5 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: BIBN4096BS 10 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: BIBN4096BS (2.5 mg and 10 mg)
Number of subjects: 7
Study: 12409542

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study: 9931170

Group type: EXPERIMENTAL
Intervention: Nonsmoking period
Number of subjects: 39
Study: 7776273

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 78
Study: 2181623

Group type: EXPERIMENTAL
Intervention: Chewable antacid tablet (30 mmol) four times daily
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine twice daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 7418711

Group type: EXPERIMENTAL
Intervention: 100 mg of hydrochlorothiazide daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.25 mg of reserpine daily
Number of subjects: 27
Study: 31812464

Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1 vaccine (15 mcg)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study: 30455160

Group type: EXPERIMENTAL
Intervention: Daily lottery incentives tied to achievement of weight loss goals
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Individually tailored environmental strategies around food intake and physical activity
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Combination of incentives and environmental strategies
Number of subjects: 344

Group type: COMPARATOR
Intervention: Standard employee wellness benefits and weigh-ins every 6 months
Number of subjects: 344
Study: 29045770

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 75
Study: 25845462

Group type: EXPERIMENTAL
Intervention: Trust Before Restraint training intervention
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 274
Study: 24506910

Group type: EXPERIMENTAL
Intervention: High dose vitamin D supplementation (2000 IU/day)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard dose vitamin D supplementation (400 IU/day)
Number of subjects: 750
Study: 22306855

Group type: EXPERIMENTAL
Intervention: HPV4 vaccine (standard schedule: 0, 2, 6 months)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HPV4 vaccine (modified schedule: 0, 3, 6 months)
Number of subjects: 200
Study: 18953552

Group type: EXPERIMENTAL
Intervention: Amphotericin B nasal spray (5 mg/ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo nasal spray (lacking amphotericin B)
Number of subjects: 30
Study: 17671281

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for up to 14 weeks
Number of subjects: 4041
Study: 15895838

Group type: EXPERIMENTAL
Intervention: Occlusal stabilization splints
Number of subjects: 21

Group type: COMPARATOR
Intervention: Palatal splints
Number of subjects: 21
Study: 12061619

Group type: EXPERIMENTAL
Intervention: Informed coaching regarding CBCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uninformed coaching regarding CBCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Witness condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suspect condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social skills correlation
Number of subjects: 0
Study: 9593411

Group type: EXPERIMENTAL
Intervention: High-heeled shoes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 20
Study: 1521362

Group type: EXPERIMENTAL
Intervention: Omron HEM‐719K
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Omron HEM‐812F
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Other oscillometric devices
Number of subjects: 18
Study: 6734693

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 60
Study: 30450551

Group type: EXPERIMENTAL
Intervention: Immediate loading (IML)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional loading (CL)
Number of subjects: 20
Study: 29156321

Group type: EXPERIMENTAL
Intervention: Clear aligners treatment after 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study: 27619782

Group type: EXPERIMENTAL
Intervention: Mirabegron add-on treatment with tamsulosin
Number of subjects: 26
Study: 24428704

Group type: EXPERIMENTAL
Intervention: DS‐ALL treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-DS ALL treatment
Number of subjects: 28
Study: 22414766

Group type: EXPERIMENTAL
Intervention: 400 mg BI 207127 TID
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 600 mg BI 207127 TID
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 800 mg BI 207127 TID
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (only TN)
Number of subjects: 57
Study: 20008622

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg/d
Number of subjects: 476

Group type: COMPARATOR
Intervention: Imatinib 400 mg/d
Number of subjects: 476
Study: 18837602

Group type: EXPERIMENTAL
Intervention: Standard treatment with brief alcohol intervention (ST-BI)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard smoking cessation treatment (ST)
Number of subjects: 236
Study: 16846576

Group type: EXPERIMENTAL
Intervention: Surgical skills laboratory on episiotomy repair
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional teaching alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Surgical skills laboratory
Number of subjects: 24
Study: 12899499

Group type: EXPERIMENTAL
Intervention: High intake of fruits and vegetables
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30000
Study: 11045266

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (ferrous sulfate 325 mg, 195 mg elemental iron, three times daily for 4 months)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous total dose iron (ITDI) (1 g iron dextran mixed in 1/2 normal saline, single infusion over 4 hours for 4 months)
Number of subjects: 9
Study: 9299215

Group type: EXPERIMENTAL
Intervention: Dorzolamide 1% eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetazolamide 250 mg tablets
Number of subjects: 0
Study: 8420437

Group type: EXPERIMENTAL
Intervention: UK-74,505 (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3731680

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 48
Study: 27742775

Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB-G2) ablation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiofrequency current (RFC) ablation
Number of subjects: 60
Study: 27821598

Group type: EXPERIMENTAL
Intervention: HOME BP online digital intervention with self-monitoring, lifestyle advice and antihypertensive drug titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HOME BP online digital intervention
Number of subjects: 0
Study: 24185749

Group type: EXPERIMENTAL
Intervention: Standardized instructor feedback for low-performer group (LPG) during training phase
Number of subjects: 20

Group type: COMPARATOR
Intervention: No feedback for high-performer group (HPG) during training phase
Number of subjects: 20
Study: 22070357

Group type: EXPERIMENTAL
Intervention: Propranolol (up to 240 mg/day for 19 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 41
Study: 19587388

Group type: EXPERIMENTAL
Intervention: CP‐690,550 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP‐690,550 15 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP‐690,550 30 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17910988

Group type: EXPERIMENTAL
Intervention: Regular abdominal exercises
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inclined abdominal exercises
Number of subjects: 9

Group type: COMPARATOR
Intervention: Resting position (Fowler)
Number of subjects: 9
Study: 15931272

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 11950129

Group type: EXPERIMENTAL
Intervention: AHCC nurse's recommendations
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Caller satisfaction (very satisfied)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Surrogates of patients under the age of 1 year
Number of subjects: 427
Study: 10347337

Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 10 mg once a day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nitrendipine (5 to 10 mg once a day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 66
Study: 8942585

Group type: EXPERIMENTAL
Intervention: Large-dose aprotinin (ALD)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Small-dose aprotinin (ASD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 61
Study: 1824803

Group type: EXPERIMENTAL
Intervention: MALG
Number of subjects: 29

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 29
Study: 6189039

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment based on two cytostatic drug combinations (cyclophosphamide, adriamycin, vincristine, methotrexate, bleomycin, 5‐fluorouracil, procarbazine)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Responders to chemotherapy
Number of subjects: 61
Study: 30009316

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 30
Study: 29930812

Group type: EXPERIMENTAL
Intervention: GSK2838232 (5-250 mg single doses, 20-200 mg repeat doses)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: GSK2838232 with RTV (up to 200 mg once or twice daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: GSK2838232 (50-100 mg without RTV, 50-250 mg with RTV)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Micronized formulation of GSK2838232
Number of subjects: 124
Study: 27081393

Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 14
Study: 24703208

Group type: EXPERIMENTAL
Intervention: Uric acid 1000 mg
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 22743295

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/d plus erlotinib 150 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo plus erlotinib 150 mg/d
Number of subjects: 30
Study: 19208703

Group type: EXPERIMENTAL
Intervention: Topical alkane vapocoolant spray (n=103)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Water spray (control, n=98)
Number of subjects: 201
Study: 17324401

Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Push Enteroscopy (PE)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE) followed by Push Enteroscopy (PE) if necessary
Number of subjects: 78
Study: 15082469

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg/day
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 11680669

Group type: COMPARATOR
Intervention: 10 mg rizatriptan (oral dose)
Number of subjects: 16
Study: 9690714

Group type: EXPERIMENTAL
Intervention: 3 months' supplementation with long chain polyunsaturated omega 3 and omega 6 fatty acids
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3 months of placebo (sunflower oil)
Number of subjects: 20
Study: 8077905

Group type: EXPERIMENTAL
Intervention: Tailored health letters
Number of subjects: 248

Group type: COMPARATOR
Intervention: Generic health letter (study 1)
Number of subjects: 248

Group type: COMPARATOR
Intervention: No health letter (study 2)
Number of subjects: 248
Study: 2666705

Group type: EXPERIMENTAL
Intervention: Combined treatment with cardiac glycosides and vasodilators (2% nitroglycerin ointment, nitrosorbide or molsidomin)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Cardiac glycosides alone
Number of subjects: 153
Study: 31916662

Group type: EXPERIMENTAL
Intervention: CGT+citalopram (CIT)
Number of subjects: 395

Group type: COMPARATOR
Intervention: CIT
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: CGT+placebo
Number of subjects: 395

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Mid-treatment QIDS-4
Number of subjects: 395
Study: 31722702

Group type: EXPERIMENTAL
Intervention: JolinchenKids intervention program
Number of subjects: 831

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 831
Study: 28057872

Group type: EXPERIMENTAL
Intervention: Etelcalcetide (5 mg initially, adjusted to 2.5-15 mg over 12 weeks)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 25534580

Group type: EXPERIMENTAL
Intervention: Oscillating positive expiratory pressure (PEP) device, thrice daily for 5 postoperative days
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard medical postoperative management and early mobilisation (Control)
Number of subjects: 203
Study: 24096919

Group type: EXPERIMENTAL
Intervention: Virtual radiography simulator
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional manikin
Number of subjects: 31
Study: 20945323

Group type: EXPERIMENTAL
Intervention: Romiplostim 750 μg administered subcutaneously weekly or biweekly
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Romiplostim 750 μg administered biweekly intravenous injections
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous injections
Number of subjects: 28
Study: 18319634

Group type: EXPERIMENTAL
Intervention: Unbalanced nutrition style (fat rich/carbohydrate low) with negative mood induction
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Balanced nutrition style with negative mood induction
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Unbalanced nutrition style (fat rich/carbohydrate low) with neutral mood induction
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Balanced nutrition style with neutral mood induction
Number of subjects: 69
Study: 16606815

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg/d)
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 12654706

Group type: EXPERIMENTAL
Intervention: 2 mg perindopril/0.625 mg indapamide
Number of subjects: 481

Group type: COMPARATOR
Intervention: 10 mg daily enalapril
Number of subjects: 481
Study: 10780101

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E (400 IU/day for 4.5 years)
Number of subjects: 0
Study: 8805730

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units intravenously in 100 mL of normal saline over 1 hour)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 340
Study: 1385635

Group type: EXPERIMENTAL
Intervention: Trospectomycin plus azteonam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin plus azteonam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple antibiotics (ampicillin plus clindamycin plus gentamicin)
Number of subjects: 0
Study: 7068888

Group type: EXPERIMENTAL
Intervention: Provocation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: No-Provocation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Abstainers)
Number of subjects: 90
Study: 30367879

Group type: EXPERIMENTAL
Intervention: Total underwater colonoscopy (TUC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard CO2 colonoscopy
Number of subjects: 121
Study: 27769117

Group type: EXPERIMENTAL
Intervention: WBR psychological intervention in addition to regular clinical follow-up care
Number of subjects: 128

Group type: COMPARATOR
Intervention: Regular clinical follow-up care
Number of subjects: 128
Study: 25943368

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) treatment for 6 to 12 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) treatment for 6 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) treatment
Number of subjects: 40
Study: 23397113

Group type: EXPERIMENTAL
Intervention: Free-floating in weightlessness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rigidly fixed posture with respect to the space station
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weightlessness
Number of subjects: 0
Study: 22234057

Group type: EXPERIMENTAL
Intervention: Non-routine dressing change (Group 1)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Routine dressing change (Group 2)
Number of subjects: 189
Study: 19355849

Group type: EXPERIMENTAL
Intervention: AN1792 (immunization with synthetic amyloid‐beta peptide)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 18246677

Group type: EXPERIMENTAL
Intervention: Acupuncture, Danshen Zhushe Ye (Saliva Injection), and routine western drugs
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine western drugs
Number of subjects: 88
Study: 15180724

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Health-care consumption
Number of subjects: 829
Study: 12558015

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brokered Case Management Program (BCM)
Number of subjects: 0
Study: 9529490

Group type: EXPERIMENTAL
Intervention: Duplex imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: CT
Number of subjects: 20
Study: 7641716

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg initial dose, with repeat doses of 50 mg as needed up to 400 mg total
Number of subjects: 523

Group type: COMPARATOR
Intervention: Morphine 5 mg initial dose, with repeat doses of 5 mg as needed up to 40 mg total
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 523

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 523
Study: 2744062

Group type: EXPERIMENTAL
Intervention: Nitrendipine (mean final dose 55 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 558739

Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cows' milk formula (Ostermilk 1)
Number of subjects: 68
Study: 31207126

Group type: EXPERIMENTAL
Intervention: Ex/HE (Healthy Eating)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ex/Diet (Hypocaloric Diet)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ex/VLCD (Very-Low-Calorie Diet)
Number of subjects: 102
Study: 28525877

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 144
Study: 26022912

Group type: EXPERIMENTAL
Intervention: Nonmuscle relaxant anesthetic technique (NMRT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cisatracurium
Number of subjects: 66
Study: 23860021

Group type: EXPERIMENTAL
Intervention: Red yeast rice capsules 600 mg twice a day for 8 weeks
Number of subjects: 30
Study: 20489029

Group type: EXPERIMENTAL
Intervention: Caspofungin with posaconazole
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Micafungin with posaconazole
Number of subjects: 67

Group type: COMPARATOR
Intervention: Caspofungin alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: Micafungin alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Coadministration of posaconazole
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Safety assessments
Number of subjects: 67
Study: 20112482

Group type: EXPERIMENTAL
Intervention: Acupuncture at Baihui (GV 20), Fengchi (GB 20), Shuaigu (GB 8), Xingjian (LR 2), Neiguan (PC 6), Sanyinjiao (SP 6) combined with oral administration of Chinese herbal decoction
Number of subjects: 62

Group type: COMPARATOR
Intervention: Simple oral administration of Chinese herbal decoction
Number of subjects: 62
Study: 17686346

Group type: EXPERIMENTAL
Intervention: Pharmaceutical treatments for fatigue in MS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical treatments for fatigue in MS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary approach to managing fatigue in MS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0